Sequencing of sipuleucel-T and androgen deprivation therapy in men with hormone-sensitive biochemically recurrent prostate cancer: A phase II randomized trial

Clinical Cancer Research

Volumn 23, Issue 10, 2017, Pages 2451-2459

  Antonarakis, Emmanuel S ^a   Kibel, Adam S ^b   Yu, Evan Y ^c   Karsh, Lawrence I ^d   Elfiky, Aymen ^e   Shore, Neal D ^f   Vogelzang, Nicholas J ^g   Corman, John M ^h   Millard, Frederick E ⁱ   Maher, Johnathan C ^j,l   Chang, Nancy N ^j   DeVries, Todd ^j,m   Sheikh, Nadeem A ^j   Drake, Charles G ^k,n  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Urology Center of Colorado   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f Carolina Urologic Research   (United States)

^g Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^h VIRGINIA MASON MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^j Dendreon   (United States)

^k JOHNS HOPKINS UNIVERSITY   (United States)

^l ABBVIE INC   (United States)

^m Juno Therapeutics   (United States)

ⁿ Department of Medicine   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; SIPULEUCEL T; TESTOSTERONE; ANDROGEN; ANTIANDROGEN; CANCER VACCINE; TISSUE EXTRACT;

ADULT; ANDROGEN DEPRIVATION THERAPY; ANTIBODY TITER; ARTICLE; BIOCHEMICALLY RECURRENT PROSTATE CANCER; CANCER RADIOTHERAPY; CANCER RECURRENCE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSPOT ASSAY; HIGH RISK PATIENT; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; AGED; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; TUMOR RECURRENCE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANDROGENS; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; T-LYMPHOCYTES; TISSUE EXTRACTS;

EID: 85020442578     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-1780     Document Type: Article

References (29)

1. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294:433-9.
2. Antonarakis ES, Feng Z, Trock BJ, Humphreys EB, Carducci MA, Partin AW, et al. The natural history of metastatic progression in men with PSA-recurrent prostate cancer after radical prostatectomy: long-term follow-up. BJU Int 2012;109:32-9.
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: prostate cancer version 1.2015. Available from: http://www.nccn.org/professionals/physician-gls/pdf/prostate.pdf.
4. Bruce JY, Lang JM, McNeel DG, Liu G. Current controversies in the management of biochemical failure in prostate cancer. Clin Adv Hematol Oncol 2012;10:716-22.
5. Drake CG, Doody AD, Mihalyo MA, Huang CT, Kelleher E, Ravi S, et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 2005;7:239-49.
6. Sutherland JS, Goldberg GL, Hammett MV, Uldrich AP, Berzins SP, Heng TS, et al. Activation of thymic regeneration in mice and humans following androgen blockage. J Immunol 2005;175:2741-53.
7. Koh YT, Gray A, Higgins SA, Hubby B, Kast WM. Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization. Prostate 2009;69:571-84.
8. Mercader M, Bodner BK, Moser MT, Kwon PS, Park ES, Manecke RG, et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A 2001;98:14565-70.
9. Gannon PO, Poisson AO, Delvoye N, Lapointe R, Mes-Masson AM, Saad F. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods 2009;348:9-17.
10. Morse MD, McNeel DG. Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses. Hum Immunol 2010;71:496-504.
11. Antonarakis ES, Drake CG. Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy. Curr Opin Oncol 2012;24:258-65.
12. Roden AC, Moser MT, Tri SD, Mercader M, Kuntz SM, Dong H, et al. Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol 2004;173:6098-108.
13. Madan RA, Gulley JL, Schlom J, Steinberg SM, Liewehr DJ, Dahut WL, et al. Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res 2008;14:4526-31.
14. Aragon-Ching JB, Williams KM, Gulley JL. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci 2007;12:4957-71.
15. Dendreon Corporation. PROVENGE® (sipuleucel-T) prescribing information. Seattle, WA: Dendreon Corporation; 2016. Available from: http://www.valeant.com/Portals/25/Pdf/PI/Provenge-PI.pdf.
16. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22.
17. Fong L, Carroll P, Weinberg V, Chan S, Lewis J, Corman J, et al. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J Natl Cancer Inst 2014;106:pii:dju268.
18. Beer TM, Bernstein GT, Corman JM, Glode LM, Hall SJ, Poll WL, et al. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin Cancer Res 2011;17:4558-67.
19. Sheikh NA, Petrylak D, Kantoff PW, Dela Rosa C, Stewart FP, Kuan LY, et al. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castrate-resistant prostate cancer. Cancer Immunol Immunother 2013;62:137-47.
20. Small EJ, Lance RS, Gardner TA, Karsh LI, Fong L, McCoy C, et al. A randomized phase II trial of sipuleucel-T with concurrent versus sequential abiraterone acetate plus prednisone in metastatic castration resistant prostate cancer. Clin Cancer Res 2015;21:3862-9.
21. GuhaThakurta D, Sheikh NA, Fan LQ, Kandadi H, Meagher TC, Hall SJ, et al. Humoral immune response against non-targeted tumor antigens after treatment with sipuleucel-T and its association with improved clinical outcome. Clin Cancer Res 2015;21:3619-30.
22. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the prostate-specific antigen working group. J Clin Oncol 1999;17:3461-7.
23. American Urological Association. PSA testing for the pretreatment staging and post treatment management of prostate cancer: 2013 revision of 2009 best practice statement. Available from: https://www.auanet.org/education/guidelines/prostate-specific-antigen.cfm.
24. Roach MIII, Hanks G, ThamesHJr, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO phoenix consensus conference. Int J Radiat Oncol Biol Phys 2006;65:965-74.
25. Graddis TJ, McMahan CJ, Tamman J, Page KJ, Trager JB. Prostatic acid phosphatase expression in human tissues. Int J Clin Exp Pathol 2011;4:295-306.
26. Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 2010;10:580-93.
27. Gulley JL, Drake CG. Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. Clin Cancer Res 2011;17:3884-91.
28. Dunn GP, Kobel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006;6:836-48.
29. Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. Urology 2013;81:1297-302.